Equities

Accelerate Diagnostics Inc

Accelerate Diagnostics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.19
  • Today's Change-0.13 / -9.85%
  • Shares traded117.30k
  • 1 Year change-83.02%
  • Beta0.6499
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.

  • Revenue in USD (TTM)12.17m
  • Net income in USD-59.05m
  • Incorporated2012
  • Employees134.00
  • Location
    Accelerate Diagnostics IncSUITE 108, 303 E 17TH AVEDENVER 80203United StatesUSA
  • Phone+1 (303) 863-8088
  • Fax+1 (302) 655-5049
  • Websitehttp://acceleratediagnostics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Telesis Bio Inc24.63m-47.13m6.82m137.00------0.277-28.31-28.3114.8012.940.32313.275.58179,802.90-59.34---67.10--60.43---183.66--3.08-35.890.2015--0.2697---1.14------
Precipio Inc15.81m-4.90m8.46m51.00--0.6449--0.5353-3.73-3.7311.608.930.877317.8517.93310,039.20-27.20-44.98-34.82-58.6839.1428.80-31.00-118.070.6201-350.950.0278--61.4639.6252.04--5.37--
Lifeloc Technologies Inc9.32m-24.41k10.21m37.00--1.6846.611.10-0.0099-0.00993.802.481.121.8314.33251,850.30-0.29250.2981-0.33540.340542.2840.75-0.2620.32451.89--0.166--9.992.03145.11-1.09-54.22--
Electro-Sensors Inc8.75m330.00k13.92m35.0042.241.0132.821.590.09610.09612.554.020.60952.487.03250,114.302.301.242.431.2949.1552.433.772.0215.41--0.00---5.252.68175.00--16.95--
Scientific Industries Inc10.79m-8.77m19.12m63.00--1.51--1.77-1.13-1.131.341.200.67621.199.31171,263.50-54.96---63.27--44.53---81.28--3.19--0.00--------------
Quarta-Rad Inc331.37k-80.73k19.59m0.00--64.89--59.13-0.0052-0.00520.02110.01930.47523.1620.99---11.58-0.0071-23.58-0.015536.0532.78-24.36-0.00410.2808-2.410.00---53.81-10.96205.14------
International Isotopes Inc.12.08m-875.02k19.87m40.00--4.91--1.64-0.0017-0.00170.02330.00770.73035.968.30302,058.00-5.29-0.1415-7.85-0.240161.7857.42-7.24-0.21980.5733-3.770.3295--9.713.42-386.58--11.54--
Winland Holdings Corp3.16m51.00k24.25m9.00384.018.56384.927.670.01320.01320.82740.59011.073.467.17--1.723.152.153.9630.0732.821.612.282.65--0.0352---11.90-2.89-1,063.64---12.94--
Accelerate Diagnostics Inc12.17m-59.05m26.24m134.00------2.16-4.54-4.540.82-1.180.29782.055.2490,805.97-144.52-75.24---94.4628.3235.08-485.31-638.551.29--2.93---5.4316.291.40--0.7307--
Multisensor AI Holdings Inc6.73m-23.28m29.71m35.00--20.51--4.42-1.95-1.950.56230.1053------192,142.90--------26.77---346.22--0.3282--0.629---25.29---67.55------
Owlet Inc58.02m-23.69m33.39m76.00------0.5754-2.87-2.876.71-2.421.062.944.30763,473.70-32.36---181.41--43.05---30.61--0.8182-43.37-----21.95--52.74------
Autoscope Technologies Corp-100.00bn-100.00bn33.56m36.00--2.15----------2.85----------14.49--15.89--78.50--19.7017.64--0.0932---6.32-3.10-47.58-25.45-14.49--
Clearsign Technologies Corp2.40m-5.19m41.30m15.00--6.18--17.19-0.1350-0.13500.06240.13420.2592--8.37160,200.00-56.02-61.67-68.60-69.4334.005.94-216.15-1,010.99----0.00--542.5135.309.80---16.81--
Data as of May 31 2024. Currency figures normalised to Accelerate Diagnostics Inc's reporting currency: US Dollar USD

Institutional shareholders

19.99%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 20241.85m8.52%
Griffin Asset Management, Inc.as of 31 Mar 20241.35m6.25%
Birchview Capital LPas of 31 Mar 2024325.24k1.50%
The Vanguard Group, Inc.as of 31 Mar 2024313.73k1.45%
Geode Capital Management LLCas of 31 Mar 2024130.59k0.60%
Cannell & Spears LLCas of 31 Mar 2024114.69k0.53%
Alyeska Investment Group LPas of 31 Mar 202480.55k0.37%
TCI Wealth Advisors, Inc.as of 31 Mar 202458.68k0.27%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202456.04k0.26%
BlackRock Fund Advisorsas of 31 Mar 202450.41k0.23%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.